Cosmos Health targets 2029 net income of $31 million under shift toward higher-margin proprietary brands and contract manufacturing

Bitget2026/10/01 19:58

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Cosmos Health set a growth plan to scale proprietary brands and contract manufacturing across its distribution network and partner markets.
Strategy targets a mix shift toward higher-margin products, with gross margins above 70% expected across key brands.
U.S. expansion centers on the 18 Series, using domestic GMP manufacturing to cut lead times and reduce tariff exposure.
R&D roadmap includes advancing CCX0722, a weight-management hydrogel capsule, pending further work and regulatory requirements.
Financial goals for 2029 include USD 200.6 million revenue, USD 44.2 million adjusted EBITDA, USD 31 million net income.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cosmos Health Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 202610011558ACCESSWRNAPR_____1230206) on October 01, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Cosmos Health targets 2029 net income of $31 million under shift toward higher-margin proprietary brands and contract manufacturing

You may also like

Crypto prices